Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Karuna Therapeutics, Inc.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers BMY KRTX
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Leadership Appointments
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Tickers KRTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.